文献速递慢性肾脏病

SGLT2抑制剂用于糖尿病肾病的预防与治疗:综述

SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
PubMed 文献 · Am J Kidney Dis · 2018-06-14

糖尿病肾病(DKD)是全球终末期肾病的主要原因,亟需减少其发生和进展的治疗手段。肾近端小管钠/葡萄糖共转运蛋白2(SGLT2)抑制已成为有效的降糖治疗,心血管安全性试验的次要效应提示其可预防或减少白蛋白尿和估算肾小球滤过率下降。本综述总结了SGLT2抑制剂的作用机制、肾脏保护假说机制及低估算肾小球滤过率糖尿病患者的当前使用建议。

要点

  • SGLT2抑制剂通过阻断近端小管葡萄糖重吸收改善全身血糖稳态。
  • 心血管安全性试验显示其可减少白蛋白尿和延缓eGFR下降。
  • 综述汇总了低eGFR糖尿病患者使用SGLT2抑制剂的当前建议。

核心结论

  • SGLT2抑制在DKD预防和治疗中具有潜力,正在进行的临床试验结果值得期待。

研究设计与样本

  • 综述总结了SGLT2抑制剂的作用机制、肾脏保护假说机制及当前使用建议。

主要发现

  • SGLT2抑制剂通过抑制近端小管葡萄糖重吸收改善全身血糖稳态。
  • 心血管安全性试验的次要效应包括预防或减少白蛋白尿和eGFR下降。

临床怎么用

  • 综述提供了低eGFR糖尿病患者使用SGLT2抑制剂的当前建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States and the world alike, and there is a great unmet need for treatments to reduce DKD development and progression. Inhibition of sodium/glucose co-transporter 2 (SGLT2) in the proximal tubule of the kidney has emerged as an effective antihyperglycemic treatment, leading to regulatory approval of several first-generation SGLT2 inhibitors for the treatment of type 2 diabetes. In follow-on clinical trials for the cardiovascular safety of the SGLT2 inhibitors, secondary effects to prevent or reduce albuminuria and decline in estimated glomerular filtration rate spurred further investigation into their potential application in DKD. This review summarizes the current understanding of mechanisms by which SGLT2 inhibitors block glucose reabsorption in the proximal tubule and improve systemic glucose homeostasis, the hypothesized mechanisms for kidney-protective effects of SGLT2 inhibition, and current recommendations for use of this class of antihyperglycemic agents in diabetic patients with low estimated glomerular filtration rates. Results of ongoing clinical trials in patients with DKD are eagerly awaited to expand knowledge of how SGLT2 inhibitors might be used for prevention and treatment.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Alicic RZ, Johnson EJ, Tuttle KR, et al. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Am J Kidney Dis. 2018. PMID: 29866460. doi:10.1053/j.ajkd.2018.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。